Ginkgo Bioworks has received a grant from the Bill & Melinda Gates Foundation to develop a novel cell-based technology for improving protein therapeutics delivery for patients in low- and middle-income countries. Ginkgo, under a grant from the Bill & Melinda Gates Foundation, will work to develop a live cell therapeutic that can produce antibodies to fight human immunodeficiency virus and/or malaria directly in the body. Ginkgo will apply its cell engineering expertise towards creating a fundamentally new cell-based therapeutic delivery modality which could change the future of biologics delivery in medicine.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DNA:
- Ginkgo Bioworks, Arbor Biotechnologies announce collaboration
- Ginkgo Bioworks, Agrivalle enter multiyear strategic partnership
- Ginkgo Bioworks and Synplogen partner in global DNA manufacturing in Japan
- Ginkgo Bioworks selected by Vivici to extend range of dairy proteins
- Ginkgo Bioworks downgraded to Market Perform yesterday at Raymond James
